Treatment and secondary prevention of venous thromboembolism in cancer.
Patients with cancer who develop venous thromboembolism (VTE) are at elevated risk for recurrent thrombotic events, even during anticoagulant therapy. The clinical picture is further complicated because these patients are also at increased risk of bleeding while on anticoagulants. In general, there are four key goals of treatment for VTE: preventing fatal pulmonary embolism (PE); reducing short-term morbidities associated with acute leg or lung thrombus; preventing recurrent VTE; and preventing the long-term sequelae of VTE (e.g., post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension). A fifth goal - minimising the risk for bleeding while on anticoagulation - is particularly warranted in patients with cancer. Traditionally, pharmacological treatment of VTE has two phases, with the transition between phases marked by a switch from a rapid-acting, parenterally administered anticoagulant (such as unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), or fondaparinux) to an oral vitamin K antagonist (e.g., warfarin). Recent clinical trials of established agents and the advent of new pharmacological options are changing this paradigm. Low-molecular-weight heparin continued for 6 months is more effective than warfarin in the secondary prevention of VTE in cancer patients without increasing the risk of bleeding and is now the preferred treatment option. Given the impact of VTE on short-term and long-term outcomes in patients with cancer, a group of health-care providers based in the United Kingdom gathered in London in 2009 to discuss recent data on cancer-associated thrombosis and to evaluate how these recommendations can be integrated or translated into UK clinical practice. This article, which is the third of four articles covering key topics in cancer thrombosis, focuses on treatment and secondary prevention of VTE in cancer patients.
Coleman
R
R
Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. R.E.Coleman@sheffield.ac.uk
MacCallum
P
P
D000925:Anticoagulants / Q000627:therapeutic use; D002405:Catheterization, Central Venous / Q000009:adverse effects; D005374:Filtration; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D017211:Treatment Failure; D054556:Venous Thromboembolism / Q000517:prevention & control / Q000628:therapy*
D000925:Anticoagulants
Br J Haematol. 2006 Aug;134(4):357-65
16822286
Lancet. 1960 Jun 18;1(7138):1309-12
13797091
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001100
15495007
Medicine (Baltimore). 1999 Sep;78(5):285-91
10499070
N Engl J Med. 1992 Nov 19;327(21):1485-9
1406880
Thromb Res. 2009 Apr;123(6):837-44
18977517
Thromb Haemost. 2009 Apr;101(4):762-9
19350123
Chest. 2008 Jun;133(6 Suppl):454S-545S
18574272
J Support Oncol. 2006 Mar;4(3):115-20
16553136
Blood. 2002 Nov 15;100(10):3484-8
12393647
N Engl J Med. 1995 Jun 22;332(25):1661-5
7760866
J Thromb Haemost. 2009 May;7(5):760-5
19245418
Arch Intern Med. 2002 Aug 12-26;162(15):1729-35
12153376
N Engl J Med. 2003 Jul 10;349(2):146-53
12853587
J Clin Oncol. 2007 Dec 1;25(34):5490-505
17968019
Circulation. 2008 Apr 1;117(13):1711-6
18347212
Arch Intern Med. 2004 Aug 9-23;164(15):1653-61
15302635
J Thromb Haemost. 2006 Sep;4(9):1950-6
16961602
J Thromb Haemost. 2007 Mar;5(3):632-4
17319909
Ann Intern Med. 2004 Feb 3;140(3):175-83
14757615
Br J Haematol. 2006 Sep;134(6):590-5
16869824
J Natl Compr Canc Netw. 2006 Oct;4(9):903-10
17020668
J Thromb Haemost. 2006 Mar;4(3):529-35
16460435
Circulation. 2004 Aug 10;110(6):744-9
15262836
N Engl J Med. 2003 Oct 30;349(18):1695-702
14585937
Lancet Oncol. 2008 Jun;9(6):577-84
18510989
Arch Intern Med. 2008 Jun 23;168(12):1261-9
18574082
Lancet. 1997 Mar 15;349(9054):759-62
9074574
Hematology Am Soc Hematol Educ Program. 2007;:165-71
18024625
Eur Heart J. 2008 Sep;29(18):2276-315
18757870
Thromb Haemost. 2008 Sep;100(3):435-9
18766259
Ann Intern Med. 2004 Jun 1;140(11):867-73
15172900
N Engl J Med. 1979 Oct 18;301(16):855-8
384248
Circulation. 2005 Jul 19;112(3):416-22
16009794
Thromb Haemost. 2008 Jul;100(1):26-31
18612534